GH Research PLC Ordinary Shares (GHRS) Stock
NASDAQ · GHRS
Key stats
- Market cap
- $1.25B
- Price / Earnings ratio
- -20.0x
- EPS (TTM)
- -$0.79
- Volume
- Loading
- 52-week high
- $31.44
- 52-week low
- $12.04
Source: third-party data provider, as of October 21, 2026
Compare with GHRS
Recent news

Stocktwits
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
GHRSJuly 27, 2026
Stocktwits
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
GHRS

Proactive Investors
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
GHRSJuly 13, 2026
Proactive Investors
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
GHRS

CNBC
How Trump's psychedelics executive order could unlock stalled cannabis reform
GHRSApril 20, 2026
CNBC
How Trump's psychedelics executive order could unlock stalled cannabis reform
GHRS

Proactive Investors
Psychedelics stocks rise after Trump order expands research, access pathways
GHRSApril 20, 2026
Proactive Investors
Psychedelics stocks rise after Trump order expands research, access pathways
GHRS
Technical indicators
- RSI 14
- 31.14
- MACD 12/26/9
- -2.15
- EMA 9 of MACD
- -2.00
- MACD histogram
- -0.15
- SMA 50
- $25.61
- Price below SMA 50
- EMA 50
- $23.93
- Price below EMA 50
- SMA 200
- $21.39
- Price below SMA 200
- EMA 200
- $21.06
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 20, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 4 analyst ratings
Strong Sell0
Sell0
Hold0
Buy4
Strong Buy0
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
346M228M114M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-48.3M
Net incomeEarnings
No data available
Source: third-party data provider
Latest news

Stocktwits
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
GHRSJuly 27, 2026
Stocktwits
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
GHRS

Proactive Investors
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
GHRSJuly 13, 2026
Proactive Investors
Psychedelics guidance from the FDA set to benefit developers, including AtaiBeckley, Jefferies says
GHRS

CNBC
How Trump's psychedelics executive order could unlock stalled cannabis reform
GHRSApril 20, 2026
CNBC
How Trump's psychedelics executive order could unlock stalled cannabis reform
GHRS

Proactive Investors
Psychedelics stocks rise after Trump order expands research, access pathways
GHRSApril 20, 2026
Proactive Investors
Psychedelics stocks rise after Trump order expands research, access pathways
GHRS

Reuters
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
GHRSApril 20, 2026
Reuters
Psychedelic drug makers rally as Trump orders FDA to expedite reviews
GHRS

Stocktwits
PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine
GHRSApril 16, 2026
Stocktwits
PBM Stock On Track For Best Session On Report Of Upcoming Trump Executive Order On Psychedelic Ibogaine
GHRS

Stocktwits
Why Is GHRS Stock Rising Today?
GHRSJanuary 5, 2026
Stocktwits
Why Is GHRS Stock Rising Today?
GHRS

Investors Business Daily
Psychedelics-Tied GH Skyrockets On FDA Go-Ahead For Depression Drug
GHRSJanuary 5, 2026
Investors Business Daily
Psychedelics-Tied GH Skyrockets On FDA Go-Ahead For Depression Drug
GHRS

Zacks Investment Research
New Strong Buy Stocks for October 25th
GHRSOctober 25, 2023
Zacks Investment Research
New Strong Buy Stocks for October 25th
GHRS
About GH Research PLC Ordinary Shares
No description available.
SectorHealthcare
IndustryBiotechnology
Employees73
CEODr. Velichka Valcheva M.D., M.Sc.
IPO DateJun 22, 2021
HeadquartersDublin, Ireland
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Velichka Valcheva M.D., M.Sc. | Chief Executive Officer | 1975 |
| Mr. Florian Schonharting M.Sc. (Econ) | Co-Founder & Non-Executive Chairman of the Board | 1969 |
| Mr. Aaron Cameron M.B.A. | Chief Operating Officer | 1985 |
| Mr. Magnus Halle | Co-Founder & MD of Ireland | 1997 |
| Ms. Julie Ryan F.C.A. | Vice President of Finance | 1986 |
Fundamentals
Valuation
Price-to-book value3.47
Profitability
Return on Equity-21.00%
Return on Assets-20.00%
EBITDA$-61.63M
Trading
Average volume325,408
Source: third-party data provider, as of October 21, 2026
Technical indicators
- RSI 14
- 31.14
- MACD 12/26/9
- -2.15
- EMA 9 of MACD
- -2.00
- MACD histogram
- -0.15
- SMA 50
- $25.61
- Price below SMA 50
- EMA 50
- $23.93
- Price below EMA 50
- SMA 200
- $21.39
- Price below SMA 200
- EMA 200
- $21.06
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 20, 2026. Technical data, not a recommendation.
Analyst views
4 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Analyst consensus:Buy
100% Buy
0% Hold
0% Sell
Analyst price target
- Low
- $39.00
- Average
- $40.75
- High
- $44.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +74.6 | +10.8 | -1.7 | |||||||||
| 2022 | -29.2 | -5.1 | +11.7 | -24.0 | -31.6 | +3.1 | +10.0 | +41.6 | -25.0 | -17.7 | +9.4 | -8.8 |
| 2023 | -8.1 | +5.4 | -23.2 | +6.6 | +24.4 | +1.9 | +2.0 | -24.9 | -3.6 | -29.1 | -11.6 | -9.4 |
| 2024 | +41.9 | +16.4 | +25.4 | -1.1 | +17.9 | -17.9 | +5.5 | -14.8 | -31.8 | +26.4 | +9.6 | -19.4 |
| 2025 | +34.0 | -43.7 | +19.8 | -11.3 | +11.7 | +5.4 | +12.9 | -1.7 | +2.7 | +5.5 | +12.0 | -10.6 |
| 2026 | +18.3 | -6.1 | -12.2 | +39.5 | +15.8 | +8.3 | +6.2 | -4.3 | -14.2 | -20.0 |
Compare stocks
Market cap
$1.25B
-
-
-
Price / Earnings ratio
-20.00
-
-
-
Price / Sales ratio
-
-
-
Dividend yield
0.00%
-
-
-
Average volume
325,408
-
-
-
Earnings per share
$-0.79
-
-
-



